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Summary Two new monoclonal antibodies - BNH9 and BNF13 - were generated by using a human lung
adenocarcinoma cell line and standard hybridoma techniques. Both were found to react with epithelial and
endothelial cells in routinely fixed and embedded tissues. Unexpected membrane labelling of some large cell
lymphomas while non-reacting with normal lymphoid cells, prompted further characterisation. The antibodies
were found to recognise red blood cell-related oligosaccharide antigens. The specificities were directed towards
H and Y determinants. A distinctive pattern of reactivity was found for BNH9 in studying 480 cases of
various lymphoid neoplasms. Strong expression of H and/or Y antigens was observed in 65/127 (51%) cases of
anaplastic large cell(ALC) (CD30+) lymphomas, which are also known to co-express epithelial membrane
antigen (EMA) frequently. Only a minority (<6%) of other non-Hodgkin's lymphomas (NHL) (CD30-,
EMA-; 208 cases) and Hodgkin's disease (HD) (CD30+, EMA-; 126 cases) were positive. Expression of H
and Y antigens was inducible on normal lymphocytes by mitogenic stimulation and by Epstein-Barr virus
infection. The data suggest remarkable biological differences of ALC lymphomas within NHL and from HD.
Blood group-related antigens constitute a family of carbo-
hydrate structures carried on both glycoproteins and glyco-
lipids of cell membranes (Hakomori & Kannagi, 1983; Feizi,
1985; Coon & Weinstein, 1986; Lloyd, 1987). These antigens,
first described on erythrocytes, have been demonstrated in
many extraerythroid normal tissues (Coon & Weinstein,
1986) and in a variety of human tumours (Feizi, 1985; Lloyd,
1987). Among these blood group antigens, H and Y deter-
minants have been the subject of a number of investigations
as to their distribution in normal and malignant epithelial
cells (Szulman, 1962; Coon & Weinstein, 1986; Kimmel et al.,
1986; Vowden et al., 1986; Schoetag et al., 1987; Le Pendu et
al., 1989; Orntoft et al., 1989). H and Y determinant expres-
sion may be related to invasive potential of urothelial car-
cinomas (Coon & Weinstein, 1986; Orntoft et al., 1989). H
and Y antigens are also present on platelets but their appear-
ance on lymphoid cells remains controversial (Lloyd, 1987;
Mollicone et al., 1988; Dunstan, 1986) and their expression
by malignant lymphomas, to our knowledge, has never been
documented.
As a part of our search for monoclonal antibodies that
react with routinely fixed and embedded tissues, we obtained
two monoclonal antibodies - BNH9 and BNF13 - directed
against blood group related H and Y determinants (Blancher
et al., 1988). The reactivity of these monoclonal antibodies
(MoAbs) with normal epithelium and malignancies ofepithe-
lial origin was not surprising, but strong labelling of cells in
anaplastic large cell (ALC) (Ki-I lymphoma) lymphomas
(Stein et al., 1985; Delsol et al., 1988) during the initial
screening, was thought both unusual and promising. The
study was therefore systematised to include as many cases as
possible from our files of non-Hodgkin's lymphomas (NHL)
including ALC lymphomas and Hodgkin's disease (HD),
with simultaneous assessment of the expression of these
antigens by normal, reactive and activated lymphocytes.
Materials and methods
Production ofantibodies
BNH9 and BNF13 MoAbs were generated by using spleno-
cytes from nude mice grafted with a human lung adenocar-
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cinoma which was also established as a permanent cell line in
culture (BUR cell line) (Al Saati et al., 1987). Non-immuno-
globulin producing myeloma cell line P3 x 63-Ag8-653 was
used as fusion partner. Fusions were performed using stan-
dard techniques (Kohler & Milstein, 1976). When hybridoma
growth could be detected, supernatants were tested for anti-
body-binding activity by immunohistochemistry on frozen
sections of the BUR tumour and human tonsils (Al Saati et
al., 1987; 1989b). Positive supernatants were further tested on
paraffin sections to detect MoAbs directed against fixative-
resistant antigens. BNH9 and BNF13 were selected because
of their reactivity on paraffin sections. Provisional data on
BNH9 (IgM) and BNF13 (?IgM/IgG2a) MoAbs was report-
ed previously (Blancher et al., 1988). Immunoprecipitation
showed that BNH9 detected two bands: one of 150 kD and a
second weak band of 120 kD, while BNF13 produced three
bands: two of 120 kD and 130 kD and one weak band of
150 kD.
Characterisation ofantigens
BNF13 antibody was submitted to the First International
Workshop on monoclonal antibodies against human red
blood cell and related antigens (Blancher et al., 1988; Oriol et
al., 1987). Further investigation showed that this antibody
reacts strongly with H type 2 antigen as well as with Y type 2
and type 2 precursor (Oriol et al., 1987). In a preliminary
study, BNH9 antibody was studied by haemagglutination
assays using red blood cells of various phenotypes. The
specificities of BNH9 and BNF13 Mobs against glycocon-
jugates were analysed by inhibition of agglutination after
incubation with well defined synthetic oligosaccharides
(Lemieux, 1978; Oriol et al., 1987) bound to an inorganic
carrier (crystalline silica) (Synsorb Chembiomed, Edmonton,
Canada).
Immunoenzymatic staining
A previously described three-stage immunoperoxidase proce-
dure was used (Delsol et al., 1988). Briefly, after incubation
with undiluted supernatants, sections were incubated in turn
with peroxidase-conjugated rabbit anti-mouse Ig (Dakopatts,
Copenhagen, Denmark) and with peroxidase-conjugated
swine anti-rabbit Ig (Dakopatts) both diluted at 1:15 in
phosphate buffered saline (PBS). Peroxidase activity was
revealed by diaminobenzidine tetrahydrochloride (DAB)
(Sigma, New Jersey, USA). Tissue samples were fixed mostly
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in ethanol-based Bouin's (Dubosq-Brazil) fluid or Bouin-
Holland, but a few were fixed in B5 or 10% formalin, to
assess the fixative-dependence of the staining intensity. A
prior trypsination step was used for paraffin sections. In the
study of lymphoid tumours, negative controls were used by
the omission of BNH9 and BNF13 MoAbs or by their
replacement with a non-relevant MoAb such as KL1; an
anticytokeratin antibody (Immunotech, Marseille, France).
Detailed immunophenotype of malignant lymphomas in our
files was known because of the use of a broad panel of
MoAbs directed against B-cell, T-cell, macrophage and acti-
vation associated antigens, and has been the subject of
previous reports (Al Saati et al., 1984; Delsol et al., 1988).
Staining of erythrocytes and blood-vessel endothelium served
as positive controls.
Reactivities with activatedperipheral blood lymphocytes,
normal lymphoid tissues, andmalignant lymphomas
Peripheral blood mononuclear cells from five healthy volun-
teers were stimulated with 1% PHA (Difco Lab) for 3 days.
PHA-stimulated cells were tested for reactivity with BNH9
and BNF13 MoAbs on day 0, 1, 2 and 3, using the alkaline
phosphatase: anti-alkaline phosphatase (APAAP) technique
(Cordell et al., 1984). In order to know whether antigens
detected by these antibodies were of the activation type
inducible by EBV (Calender et al., 1987), five EBV-positive
lymphoblastoid cell lines from own laboratory were tested by
staining with the APAAP technique.
The reactivities of BNH9 and BNF13 MoAbs were investi-
gated on normal tissues as well as reactive lymph nodes
(n = 20) and tonsils (n = 10). In the initial study of the
reactivity of these antibodies with malignant lymphomas, we
noted an unexpected reactivity of some cases of ALC lym-
phomas (Ki-I lymphomas) described by Stein et al. (1985;
Delsol et al., 1988). This finding prompted us to systema-
tically investigate a large series of ALC lymphomas (n = 127)
as well as NHL of non-anaplastic type (n = 208) and cases of
HD of all subtypes (n = 145).
Reactivities with non-lymphoid normal tissues andneoplasms
A variety of surgically excised non-lymphoid human tumours
from our tissue bank (n = 153) were tested. The reactivities
with normal tissues were assessed on paraffin sections using
the 'sausage' tissue block method (Battifora, 1986).
Results
Adsorption with synthetic oligosaccharides
The results of haemagglutination-inhibition with synthetic
oligosaccharides and tissue reactivities showed that BNF13
and BNH9 have H-related specificity, but react with different
epitopes of the H-antigen. BNF13 was totally adsorbed by H
type 2 suggesting binding with an epitope containing the
trisaccharide alphaFuc(I-2)BetaGal(I-4)BetaGlcNAc and
dependant upon the Beta(I-4)galactosyl linkage. The re-
activity of BNH9 MoAb suggested a binding with an epitope
containing either the alphaFuc(I-2)BetaGal(I-4)BetaGlcNac
or alphaFuc(1-2)BetaGal(I-3)BetaGlcNAc trisaccharide pre-
sent respectively on H and Y type 2 and H type 1. However,
the adsorption by H type 4 could indicate that the reactivity
of BNH9 MoAb was dependant on the disaccharide compo-
nent alphaFuc(1-2)BetaGal present on H type 1, H type 2, H
type 4 and Y type 2. These findings were further confirmed
by the complete absence of immunostaining of epithelium
and blood vessels when absorbed supernatants were tested
for their activity on normal human tonsils.
Reactivities with PHA-stimulated lymphocytes and
Epstein-Barr Virus (EBV) + lymphoblastoid cell lines
Many PHA-transformed lymphocytes showed an extremely
weak, diffuse cytoplasmic staining with BNH9 and BNF13
antibodies by the sensitive APAAP procedure. In addition,
except for one patient, a small percentage of cells showing a
clear membrane staining with both antibodies, emerged on
day 3.
All but one EBV + lymphoblastoid cell lines showed
1-3% of cells positive for BNH9 and BNF13 MoAbs. The
staining was strong and mainly membrane associated (Figure
1). These cell lines were of polyclonal B-lymphocytes express-
ing several activation antigens including the Ki-l (CD30)
antigen and the recently described CDw7O antigen (Al Saati
et al., 1989a).
Reactivities with normal hematopoietic tissues
Immunoperoxidase staining on frozen and paraffin sections
gave similar results. On reactive lymph nodes, endothelial
cells including post-capillary venules, reacted strongly with
both antibodies (Figure 2). In addition, stellate reticulum
cells of the marginal sinus were also strongly positive for the
two MoAbs. By contrast, histiocytes, plasma cells and lym-
phoid cells including germinal centre cells and immunoblasts
in the paracortical area, were consistently negative. In only
two reactive lymph nodes, scarce positive small lymphocyte-
like cells were found. Erythroblasts were considered as possi-
ble candidates for this positive reactivity. In normal spleen,
only endothelial cells and sinus lining cells were found to be
strongly positive. Variation of fixatives did not make a signi-
ficant difference in the staining patterns. Staining in several
randomly chosen bone marrow biopsy specimens was confin-
ed to endothelial cells, erythroblasts and a variable number
of megakaryocytes. Myeloid cells were unequivocally nega-
tive.
Figure 1 Reactivity of BNH9 antibody with Epstein-Barr virus
positive lymphoblastoid cell line. Clear and strong membrane
staining of two cells. APAAP staining technique x 800.
Figure 2 BNH9 antibody staining ofa fixed and paraffin-embed-
ded reactive lymph node. Strong staining of endothelial cells
(including postcapillary venules). Note absence of staining of
both germinal centre and mantle zone lymphocytes. Immunoper-
oxidase with nuclear counterstain x 312.RBC-RELATED ANTIGEN EXPRESSION BY LYMPHOMAS 323
Reactivities with malignant lymphomas and related disorders
Because of the fixation-resistant property of the antigens,
only paraffin sections were used in the extended evaluation.
However, in the early stages, BNH9 antibody consistently
stained more numerous malignant cells than BNF13. More-
over, ten cases which were positive for BNH9 MoAb showed
no positive cells with BNF13, while the opposite staining
pattern, i.e. BNH9-/BNF13+, was not observed in any
case. Thus, the study was mainly focused on the reactivity of
BNH9 with paraffin embedded tissue sections from patients
with lymphomas and related disease and the results are
shown in Tables I, II and III.
Anaplastic large cell (ALC) lymphomas (Tables I and II)
Tissues in 65 of the 127 cases (51%) reacted with BNH9;
while only 25% of these tumours were also positive for
BNF13. In a previous report (Delsol et al., 1988), we had
subdivided ALC lymphomas on the basis of the co-expres-
sion of Ki-l (CD30) and epithelial membrane antigens
(EMA) into three types: Ki-l + /EMA +; Ki-l + /EMA -
and Ki-l - /EMA + . In the present study, 61/108 cases
(56.5%) of Ki-l + /EMA + ALC lymphomas were found to
be positive for BNH9. Among tumours expressing either the
Ki-l antigen (nine cases) or EMA (ten cases) only one (11%)
and three (30%) cases respectively, were positive for BNH9.
The number of positive cells varied greatly from case to case
but in the majority (40/65) of BNH9 positive cases, 50% to
100% ofmalignant cells were labelled. There were three cases
in which BNH9 stained only 1% of malignant cells. What-
ever the number ofpositive cells, the staining was intense, on
the cell membranes, and commonly associated with a dot-like
pattern in the paranuclear Golgi area (Figure 3). No other
cells (except the positive control endothelial cells), were stain-
ed in BNH9 positive tumours. In addition, it was to noticed
that, BNH9 positive ALCs were mainly ofeither T-cell origin
(59%) or null phenotype (31%) (Table I). A significant
difference was noted in the reactivities of BNH9 with ALC
lymphomas in children as compared to those in adults. In
Table I Anaplastic large cell lymphomas. Correlations ofreactivity of
BNH9 with phenotype
Type 1 Type 2 Type 3
Phenotype (BNH9 +/tested) (BNH9 +/tested) (BNH9 +Itested)
T-cell 13/29 0/2 ND
B-cell 1/5 ND 0/2
B + T 1/2 0/2 0/2
Null 7/12 ND ND
Undetermined* 39/60 1/5 3/6
Total 61/108 (56.5%) 1/9 (11.1%) 3/10 (30%)
Types ofanaplastic large cell lymphomas as previously reported (ref.
Delsoletal., 1988): Type 1: Ki-1 +, EMA +;Type2: Ki-l + , EMA -;
Type 3: Ki-1- , EMA + . - Ki-l = CD30. - EMA = epithelial memb-
raneantigen; ND: notdone; *Undetermined becauseofnonavailability
of frozen tissue. These cases were negative with anti-T, anti-B, and
anti-macrophage antibodies reactive on fixed and paraffin-embedded
specimens.
Table II BNH9 monoclonal antibody reactivity with malignant lym-
phomas and Hodgkin's disease
No of
cases BNH9 +
Anaplastic large cell (ALC) lymphomas 127 65 (51%)
Non-Hodgkin's lymphomas other than ALC 208 12 (5.7%)
Hodgkin's disease 145
lymphocyte predominance (LP) 19 4 (21%)
nodular sclerosis (NS) 49 1
mixed cellularity (MC) 66 1
lymphocyte depletion (LD) 2 1
unclassified 9 3
Details of the reactivities of non-Hodgkin's lymphomas other than
ALC aregiven in Table III. Excluding LPsubtypeofHodgkin's disease
(see Chittal et al., 1990 for reasons of exclusion), some classic
Reed-Sternberg cells were positively stained in 6/126 (<5%) cases.
Table III Reactivities of non-Hodgkin's lymphomas (other than































































*Positive case consisted of immature plasmablasts. N.B., 11/12
BNH9 positive cases ofnon-Hodgkin's lymphomas (other than ALC)
were morphologically high grade type.
Figure 3 A case of anaplastic large cell lymphoma stained with
BNH9 antibody. Virtually all large cells show crisp membrane
labelling. Strong staining of endothelial cells serves as positive
control x 312. Inset: paranuclear dot-like reaction product in
association with membrane staining at a higher magnification.
Immunoperoxidase with nuclear counterstain x 800.
children 29/41 (70.7%) tumours were positive for BNH9 as
compared to 36/86 (41.8%) in adults (P = 0.0023). The
observations need further detailed assessment.
The RBC phenotype was known in 46 patients. No signi-
ficant differences were found between RBC phenotype, the
secretor status and the reactivity with BNH9.
NHL other than ALC (Table III) Only 12 of 208 (5.7%)
NHL were positive for BNH9. In these cases, the staining
was intense and membrane associated similar to that of ALC
lymphomas. Noteworthy was the finding that 11/12 these
positive cases of NHL, were high grade lymphomas by mor-324 G. DELSOL et al.
phologic criteria. True 'malignant histiocytosis' and histio-
cytosis X did not react with BNH9.
The RBC phenotype was known in 32 patients in NHL.
Similar to ALC lymphomas, no significant differences were
found between their RBC phenotype, secretor status and the
reactivity with BNH9.
Hodgkin's disease (HD) (Table II) In four of the 19 cases
of lymphocyte predominance HD, some lympho-histiocytic
cells (L and H type) reacted with BNH9 antibody. Interest-
ingly, one of these four cases, reported in a separate publica-
tion, transformed into high grade large B-cell lymphoma, the
cells of which were also positive for BNH9 (Chittal et al.,
1990). No staining on Reed-Sternberg cells and variants was
found in 120 cases; only endothelial cells (used as positive
controls), were stained (Figure 4). In only 6/126 (4.7%) cases
of the other histological types of Hodgkin's disease (nodular
sclerosis, mixed cellularity, lymphocyte depletion and un-
classified: total = 126 cases), rare morphologically typical
Reed-Sternberg cells were found to be positive for BNH9.
Reactivities with non-lymphoid normal tissues and tumours
A large panel of normal human tissues obtained from para-
ffin embedded biopsy specimens (normal multi-tissue block)
were stained to specify the reactivities of BNH9 and BNF13.
In all organs, endothelial cells were strongly labelled with the
two antibodies. Minor differences were found in the reac-
tivities of BNH9 and BNF13 on cells other than endothelial
cells. Squamous cells of the skin, tonsil and oesophagus were
positive for both antibodies. Sebaceous glands were labelled,
in addition to epidermal cells and sweat glands, but only with
BNF13. Varying proportions of glandular structures of the
bronchus, gastrointestinal tract, salivary glands and pancreas
(except for islets cells) were also stained. A small proportion
of tubules in kidney were labelled. Except for the usual
reactivity with blood vessels, no significant staining was
observed in liver, heart, brain, testis and ovary.
Reactivities of BNH9 and BNF13 antibodies with non-
lymphoid tumours were assessed on frozen and paraffin sec-
tions using the multi-tumour (sausage) tissue block method.
Among 153 tested 76 were positive for BNH9. Major positive
reactivities were found with carcinomas of the lung (squa-
mous cell: 9/9; adenocarcinoma: 8/9; small cell carcinoma:
3/12), thyroid (7/12), gastrointestinal tract (eosophagus: 1/2;
gastric: 6/8; colon: 3/9), pancreas (1/2), liver (1/4), breast
(10/11), kidney (1/7), urinary bladder (4/5), prostate (3/5) and
uterine cervix (2/2). Soft tissue tumours were negative for
BNH9 with the exception of angiosarcoma and synovial
sarcoma. Glial tumours and meningiomas were negative.
Figure 4 Staining of a case of Hodgkin's disease with BNH9
antibody in which a classic Reed-Stemnberg cell (short arrow) is
negative whereas strong staining of endothelial cells is positive
control. Immunoperoxidase with nuclear counterstain x 312.
Discussion
The results suggest that BNH9 and BNF13 are 'anti-H'
antibodies but react with different epitopes of the H-antigen.
BNH9 antibody reacted with H type 1, H type 2, H type 4
and Y (type 2) (Oriol et al., 1987). The lack ofadsorption by
H type 3 synsorbs is difficult to explain. BNF13 antibody
was adsorbed only by H type 2 and Y type 2 and type 2
precursor, identical to previously obtained results (Oriol et
al., 1987). The findings obtained so far, are relevant to the
reactivities of these antibodies on paraffin sections, because
carbohydrates rich glycoproteins are usually resistant to
various fixatives (Stross et al., 1989).
As expected, these two antibodies reacted with erythrocytes
and endothelial cells, since H antigens are expressed on these
cells regardless of the secretor status (Kimmel et al., 1986; Le
Pendu et al., 1989). Similarly, the reactivity of many normal
epithelial cells as well as many carcinoma cells of diverse
origin, is in agreement with previous studies on the tissue
distribution of H and Y antigens (Feizi, 1985; Coon &
Weinstein, 1986; Vowden et al., 1986).
Lymphocytes are known to express ABH and Lewis deter-
minants under the control of the Se and Le genes (Dunstan,
1986; Oriol et al., 1980). However, these antigens are
absorbed from the plasma and appear to be primarily of H
type 1 (Mollicone et al., 1988; Oriol et al., 1980). Lympho-
cytes were unreactive with BNH9 and BNF13 MoAbs by
cytofluorometric analysis (data not shown). Lymphoid cells
were also consistently negative in reactive lymph nodes.
These antibodies reacted only with endothelial cells of blood
vessels in all lymph nodes, but occasional stellate cells of the
marginal sinus appeared to be positively stained. Rare cells
with appearance of lymphocytes found in two cases, were
likely erythroblasts.
Due to the acquisition of H and Y antigens by ALC
lymphomas, which are known to arise from activated lym-
phoid cells, there was a high probability that these antigens
could be promoted on PHA-stimulated blood lymphocytes.
We did observe clear staining with BNH9 and BNF13
MoAbs not only with PHA-stimulated lymphocytes but also
in a small percentage of cells from EBV + lymphoblastoid
cell lines. This latter finding is in agreement with that of
Mollicone and co-workers (1988) who stressed that the H
gene product can indeed be expressed in lymphoblastoid cell
lines. Changes of glycosylation pattern have been described
in other virus infected cells such as Herpes virus infected cells
(Ray & Blough, 1978) and it has also been recently reported
that hapten Y could be expressed by lymphocytes infected
with the human immunodeficiency (HIV) virus (Adachi et al.,
1988). However, we did not find staining of lymphocytes in
reactive lymph nodes from known HIV-seropositive patients,
with BNH9 and BNF13 MoAbs.
Although not expressed on normal lymphocytes, H deter-
minant was previously found to be expressed in B acute
lymphoblastic leukaemias (Koller et al., 1987). Expression of
H and/or Y antigens detected by BNH9 MoAb in over 50%
of ALC lymphomas is in striking contrast to its rare occur-
rence in the other lymphoid neoplasms (5.7% of NHL in our
cases). As previously demonstrated, the expression of blood
group antigens in normal tissues may be dependent on the
secretor status, some of these antigens being taken up from
the serum, particularly on lymphocytes (Lloyd, 1987; Molli-
cone et al., 1988; Oriol et al., 1980). No significant correla-
tion was found with BNH9 staining with either the secretor
status or with the blood groups of our patients. In addition,
passive absorption from serum was ruled out by the finding,
that in the majority of positive cases, the membrane staining
was associated with a dot-like staining in the Golgi area. This
paranuclear staining pattern is consistent with the fact that
glycoproteins and glycolipids are glycoslated in the Golgi
apparatus (Alberts et al., 1983). Lastly, the wide disparity
between BNH9 staining in ALC lymphomas and other lym-
phoid neoplasms, makes the passive absorption phenomenon
unlikely. Thus, expression of H and Y antigens may repre-
sent biological distinctiveness of ALC lymphomas amongRBC-RELATED ANTIGEN EXPRESSION BY LYMPHOMAS 325
NHL. Since these antigens were inducible by stimulation of
lymphocytes by mitogens such as PHA or by EBV infection,
they are candidates as activation antigens, like other activa-
tion markers such as the Ki-I (CD30) antigen (Stein et al.,
1985) and the CDw7O antigen (Al Saati et al., 1989a). How-
ever, the reactivity with BNH9 antibody suggests that ALC
lymphomas occurring in adults are more heterogeneous than
similar tumours in children (41.8 vs 70.7% were respectively
positive for BNH9).
In non-lymphoid tumours e.g. urothelial carcinomas, dra-
matic changes in the expression of blood group antigens such
as the loss of ABH and Lea antigens, are usually associated
with a more aggressive potential, compared to those in which
these antigens are preserved (Coon & Weinstein, 1986; Orn-
toft et al., 1989). Preliminary results using univariate analysis
suggest that adults with BNH9 positive ALC lymphomas fare
worse in comparison to those with BNH9 negative tumours.
These findings need to be confirmed by multivariate analysis
and controlled prospective studies. No such differences was
found in children.
A possible diagnostic use of BNH9 antibody, is in making
the distinction between neoplastic cell-rich HD and ALC
lymphomas; a problem expected to arise in approximately
10% of cases in our experience. As found in this study, ALC
lymphomas, more often than not, show CD30 +, EMA +,
BNH9 + phenotype whereas typical Reed-Sternberg cells in
HD most frequently co-express CD15 and CD30 antigens
(Chittal et al., 1988). EMA is not expressed by classic Reed-
Stemnberg cells (Chittal et al., 1988). Similarly, we found the
antigens detected by BNH9 antibody to be expressed rarely
by Reed-Sternberg cells in HD (Table II). Even though the
differential expression of CD15 (X-hapten) could further
assist in the separation of these entities, caution needs to be
exercised, as up to 22% of cases of ALC lymphomas may
express the CD15 antigen (Delsol et al., 1988). The frequent
expression of EMA and H and Y antigens by ALC lym-
phomas indicates that HD and ALC lymphomas may not be
as closely related entities as previously suggested on the basis
of CD30 expression (Stein et al., 1985).
The mechanism responsible for expression of H and Y
antigens by ALC lymphomas remains to be clarified, but
there may be possible explanations. As discussed above,
a viral infection could be involved in abnormal glucosyl-
transferase activity. Alternatively, an abnormality of glyco-
syltransferase activity may be the result of a specific
chromosomal abnormality found in ALC lymphomas. Mason
et al. (1990) have demonstrated that ALC lymphomas fre-
quently show a translocation involving exchange of material
between chromosomes 2 and 5 at bands 2p23 and 5q35. We
found the same translocation in two BNH9-positive ALC
lymphomas of our series in which cytogenetic analysis was
performed (data not shown). Much further investigation will
be needed to clarify this important issue.
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